The Division of Blood Diseases & Resources, NHLBI (DBDR) is a leader in research on the causes, prevention, and treatment of non-neoplastic blood diseases. DBDR assumes a major responsibility in ensuring the adequacy and safety of the nation’s blood supply. It also supports scientific advances in stem cell biology and new gene and cell-based therapies developed to repair and regenerate human tissues and organs. The DBDR is divided into three branches that are structured to facilitate team science in priority areas of blood science. Together, the branches foster the training of the next generation of blood scientists, coordinate blood research activities, and promote communication across the Division, the NHLBI, the NIH, and partner federal agencies.
The Blood Epidemiology & Clinical Therapeutics Branch provides oversight, support, and stimulation of epidemiologic, clinical trial, and implementation research throughout the spectrum of blood science. This spectrum includes benign blood diseases, as well as cell therapies such as hematopoietic stem cell transplants, transfusion products, and novel cell therapies. This branch also helps develop and disseminate data science resources in patient-reported outcomes.
The Division of Blood Diseases and Resources (DBDR) is seeking exceptional Clinical Trials Specialists with experience in the management and oversight of ethical, regulatory, and safety aspects of observational studies and clinical trials. The ideal candidate must be familiar with the role of Monitoring Boards (DSMBs/OSMBs), administration and coordination of Committees/Boards, work well in a team environment and have excellent written and oral communication skills.
Email Simone Glynn (firstname.lastname@example.org), MD., MSc., MPH, Chief, Blood Epidemiology & Clinical Therapeutics Branch, Division of Blood Diseases & Resources, NHLBI for more information.
For more information and to apply, visit USAJobs and access the NIH, National Heart, Lung, and Blood (NHLBI) for Clinical Trials Specialist, open November 29, 2021 through December 8, 2021.